TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Sinovac launches late-stage trial for potential COVID-19 vaccine in Indonesia

News Desk (Reuters)
Jakarta, Indonesia/Beijing, China
Tue, August 11, 2020

Share This Article

Change Size

Sinovac launches late-stage trial for potential COVID-19 vaccine in Indonesia A nurse holds China's Sinovac vaccine, a potential vaccine for the COVID-19, at the Sao Lucas Hospital of the Pontifical Catholic University of Rio Grande do Sul (PUCRS), in Porto Alegre, Brazil on Saturday.Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma. (REUTERS/Diego Vara)

C

hina's Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.

The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

CoronaVac is already undergoing a late-stage trial in Brazil slated for as many as 9,000 people.

Its Indonesia trial comes as Southeast Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of Tuesday. The trial has so far recruited 1,215 people and will last six months.

A ceremony for the launch on Tuesday in Bandung, West Java, was attended by Indonesia's President Joko Widodo.

"The threat of COVID-19 will not subside until a vaccine is given to all the people," Widodo said.

Sinovac expects to also test the vaccine candidate in Bangladesh.

Separately, Sinovac late on Monday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.

In the Phase 2 clinical trial involving 600 participants in China, the candidate did not cause any serious side effect and the rate of fever was relatively low compared with other COVID-19 candidates, the paper showed ahead of peer review.

Sinovac has to test its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

 

 

{

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.